INO
INO
NASDAQ · Biotechnology

Inovio Pharmaceuticals Inc

$1.43
-0.03 (-2.05%)
Financial Highlights (FY 2026)
Revenue
315.1K
Net Income
-407,771,247
Gross Margin
60.1%
Profit Margin
-130,006.0%
Rev Growth
-81.5%
D/E Ratio
—
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 60.1% 60.1% 61.2% 61.2%
Operating Margin -132,877.4% -119,589.7% -0.7% -0.8%
Profit Margin -130,006.0% -123,505.7% -0.8% -0.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 315.1K 1.70M 29.02M 30.84M
Gross Profit 189.5K 1.02M 17.76M 18.88M
Operating Income -418,706,083 -2,033,650,699 -216,172 -232,129
Net Income -407,771,247 -1,980,540,325 -227,719 -278,307
Gross Margin 60.1% 60.1% 61.2% 61.2%
Operating Margin -132,877.4% -119,589.7% -0.7% -0.8%
Profit Margin -130,006.0% -123,505.7% -0.8% -0.9%
Rev Growth -81.5% -81.5% +16.9% +11.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 56.78M 51.84M
Total Equity — — 78.40M 79.95M
D/E Ratio — — 0.72 0.65
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -409,976,998 -2,101,878,834 -290,155 -260,150
Free Cash Flow — — -255,634 -361,408